Literature DB >> 12151851

Oxidized lipids as mediators of coronary heart disease.

Mohamad Navab1, Susan Y Hama, Srinu T Reddy, Carey J Ng, Brian J Van Lenten, Hillel Laks, Alan M Fogelman, Srinu T Ready.   

Abstract

PURPOSE OF REVIEW: To summarize the recent evidence on the physiological relevance of the view that LDL lipid oxidation may play a major role in the inflammatory reaction that leads to or amplifies atherogenesis. Oxidation of LDL phospholipids containing arachidonic acid at the sn-2 position occurs when a critical concentration of 'seeding molecules' derived from the lipoxygenase pathway is reached in LDL. This generates a series of biologically active, oxidized phospholipids that mediate the cellular events seen in the developing fatty streak. RECENT
FINDINGS: We have observed that LDL from mice that are genetically predisposed to diet-induced atherosclerosis is highly proinflammatory when the mice are maintained on an atherogenic diet, when they are injected with LDL-derived oxidized phospholipids, or once they are infected with influenza A virus. Patients with coronary atherosclerosis also had highly proinflammatory LDL, despite having normal blood lipid levels or normal plasma HDL levels.
SUMMARY: We and others have hypothesized that HDL and LDL-derived oxidized phospholipids may be part of a system of nonspecific innate immunity. We therefore propose that determination of HDL capacity against LDL oxidation and the detection of proinflammatory HDL may be a useful marker of susceptibility to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151851     DOI: 10.1097/00041433-200208000-00003

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  18 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response.

Authors:  Stanley L Hazen; Guy M Chisolm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

3.  Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity.

Authors:  Hagai Tavori; Alexandra M Fenton; Deanna L Plubell; Sara Rosario; Elisabeth Yerkes; Rayna Gasik; Joshua Miles; Paige Bergstrom; Jessica Minnier; Sergio Fazio; Nathalie Pamir
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

4.  Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis.

Authors:  Asokan Devarajan; Noam Bourquard; Susan Hama; Mohamad Navab; Victor R Grijalva; Susan Morvardi; Catherine F Clarke; Laurent Vergnes; Karen Reue; John F Teiber; Srinivasa T Reddy
Journal:  Antioxid Redox Signal       Date:  2010-09-06       Impact factor: 8.401

5.  Impaired hepatic insulin signalling in PON2-deficient mice: a novel role for the PON2/apoE axis on the macrophage inflammatory response.

Authors:  Noam Bourquard; Carey J Ng; Srinivasa T Reddy
Journal:  Biochem J       Date:  2011-05-15       Impact factor: 3.857

6.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

Review 7.  Oxidized low-density lipoprotein.

Authors:  Sampath Parthasarathy; Achuthan Raghavamenon; Mahdi Omar Garelnabi; Nalini Santanam
Journal:  Methods Mol Biol       Date:  2010

8.  Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.

Authors:  Jennifer M P Woo; Zhuofeng Lin; Mohamad Navab; Casey Van Dyck; Yvette Trejo-Lopez; Krystal M T Woo; Hongyun Li; Lawrence W Castellani; Xuping Wang; Noriko Iikuni; Ornella J Rullo; Hui Wu; Antonio La Cava; Alan M Fogelman; Aldons J Lusis; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

9.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

Authors:  Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Vascular dysfunction in a murine model of severe hemolysis.

Authors:  Anne C Frei; YiHe Guo; Deron W Jones; Kirkwood A Pritchard; Karen A Fagan; Neil Hogg; Nancy J Wandersee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.